摘要
Iron is required for many enzymes which are critical for cellular functions and plays an important role in oxygen carrying proteins, e.g. hemoglobin. But it can be toxic when present in excess. Therefore, the total body iron store should be kept within defined limits. When there is excess of iron in the body, it is called iron overload. If it is untreated, it will damage the target organs, including the heart, liver and endocrine organs. Clinically we can use phlebotomy or iron chelators to treat iron overload. In the past 3 or 4 decades, only one available iron chelator "deferoxamine" can be used. However, poor compliances and inconvenience are major problems. During the past few years the advances on iron chelation research has been impressive, leading to the development of new oral iron chelators including deferiprone and deferasirox. The new treatment options greatly enhance the efficacy of iron chelation for preventing and treating the iron overload complications. Whichever iron chelator is chosen, patients should be closely monitored both for effectiveness of therapy and for toxic side effects.
| 原文 | English |
|---|---|
| 頁（從 - 到） | 48-57 |
| 頁數 | 10 |
| 期刊 | Journal of Internal Medicine of Taiwan |
| 卷 | 20 |
| 發行號 | 1 |
| 出版狀態 | Published - 2009 二月 1 |
指紋
All Science Journal Classification (ASJC) codes
- Internal Medicine
引用此文
}
New progress in iron chelation therapy. / Chen, Ya-Ping; Wu, Hung Chang; Yeh, Yu-Min; Chang, Kwang Yu; Chiu, Wei-Hsin; Su, Wen-Pin; Lin, Peng-Chan; Yen, Chia-Jui; Su, Wu-Chou; Chen, Tsai-Yun.
於: Journal of Internal Medicine of Taiwan, 卷 20, 編號 1, 01.02.2009, p. 48-57.研究成果: Article
TY - JOUR
T1 - New progress in iron chelation therapy
AU - Chen, Ya-Ping
AU - Wu, Hung Chang
AU - Yeh, Yu-Min
AU - Chang, Kwang Yu
AU - Chiu, Wei-Hsin
AU - Su, Wen-Pin
AU - Lin, Peng-Chan
AU - Yen, Chia-Jui
AU - Su, Wu-Chou
AU - Chen, Tsai-Yun
PY - 2009/2/1
Y1 - 2009/2/1
N2 - Iron is required for many enzymes which are critical for cellular functions and plays an important role in oxygen carrying proteins, e.g. hemoglobin. But it can be toxic when present in excess. Therefore, the total body iron store should be kept within defined limits. When there is excess of iron in the body, it is called iron overload. If it is untreated, it will damage the target organs, including the heart, liver and endocrine organs. Clinically we can use phlebotomy or iron chelators to treat iron overload. In the past 3 or 4 decades, only one available iron chelator "deferoxamine" can be used. However, poor compliances and inconvenience are major problems. During the past few years the advances on iron chelation research has been impressive, leading to the development of new oral iron chelators including deferiprone and deferasirox. The new treatment options greatly enhance the efficacy of iron chelation for preventing and treating the iron overload complications. Whichever iron chelator is chosen, patients should be closely monitored both for effectiveness of therapy and for toxic side effects.
AB - Iron is required for many enzymes which are critical for cellular functions and plays an important role in oxygen carrying proteins, e.g. hemoglobin. But it can be toxic when present in excess. Therefore, the total body iron store should be kept within defined limits. When there is excess of iron in the body, it is called iron overload. If it is untreated, it will damage the target organs, including the heart, liver and endocrine organs. Clinically we can use phlebotomy or iron chelators to treat iron overload. In the past 3 or 4 decades, only one available iron chelator "deferoxamine" can be used. However, poor compliances and inconvenience are major problems. During the past few years the advances on iron chelation research has been impressive, leading to the development of new oral iron chelators including deferiprone and deferasirox. The new treatment options greatly enhance the efficacy of iron chelation for preventing and treating the iron overload complications. Whichever iron chelator is chosen, patients should be closely monitored both for effectiveness of therapy and for toxic side effects.
UR - http://www.scopus.com/inward/record.url?scp=63049100818&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=63049100818&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:63049100818
VL - 20
SP - 48
EP - 57
JO - Journal of Internal Medicine of Taiwan
JF - Journal of Internal Medicine of Taiwan
SN - 1016-7390
IS - 1
ER -